¼¶±ð: Ôº³¤
UID: 74482
¾«»ª: 0
·¢Ìû: 1326
ÍþÍû: 15 µã
»ý·Öת»»
ÓÞÓÞ±Ò: 1412 YYB
ÔÚÏß³äÖµ
¹±Ï×Öµ: 0 µã
ÔÚÏßʱ¼ä: 33(Сʱ)
×¢²áʱ¼ä: 2009-08-19
×îºóµÇ¼: 2022-08-22
Â¥Ö÷  ·¢±íÓÚ: 2018-10-02 10:05

 EGFRÍ»±ä·Î°©Ò»ÏßÖÎÁÆÐÂÑ¡Ôñ£¡»ÔÈðµÚ¶þ´ú°ÐÏò¿¹°©Ò©Vizimpro»ñÃÀ¹úFDAÅú×¼£¬ÁÆЧµõ´ò°¢Ë¹Àû¿µÒ×Èðɳ£¡

ÃÀ¹úÖÆÒ©¾ÞÍ·»ÔÈð(Pfizer)½üÈÕÐû²¼£¬ÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö(FDA)ÒÑÅú×¼µÚ¶þ´úEGFR°ÐÏòÒ©ÎïVizimpro(dacomitinib£¬´ï¿ËÌæÄá)£¬ÓÃÓÚ¾­FDAÅú×¼µÄÒ»¿î¼ì²âÊÔ¼ÁºÐ¼ì²â֤ʵ´æÔÚ±íƤÉú³¤Òò×ÓÊÜÌå(EGFR)µÚ19ºÅÍâÏÔ×Óȱʧ»ò21ºÅÍâÏÔ×ÓL858RÖû»Í»±äµÄתÒÆÐÔ·ÇСϸ°û·Î°©(NSCLC)»¼ÕßµÄÒ»ÏßÖÎÁÆ¡£

    ´Ë´ÎÅú×¼ÊÇ»ùÓÚIIIÆÚÁÙ´²Ñо¿ARCHER 1050µÄÊý¾Ý¡£¸ÃÑо¿ÊÇÒ»ÏîËæ»ú¡¢¿ª·Å±êÇ©¡¢Í·¶ÔÍ·IIIÆÚÑо¿£¬ÔÚЯ´øEGFR¼¤»îÍ»±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔNSCLC»¼ÕßÖпªÕ¹£¬ÆÀ¹ÀÁËVizimproÏà¶ÔÓÚ°¢Ë¹Àû¿µµÚÒ»´úEGFR°ÐÏòÒ©ÎïIressa(Ò×Èðɳ£¬Í¨Ó*************************û£ºgefitinib£¬¼ª·ÇÌæÄá)ÓÃÓÚÒ»ÏßÖÎÁƵÄÁÆЧºÍ°²È«ÐÔ¡£Ö÷ÒªÖÕµãÊÇÎÞ½øÕ¹Éú´æÆÚ(PFS)£¬´ÎÒªÖÕµãΪOS¡£

    Ñо¿Êý¾ÝÏÔʾ£¬ÓëIressaÖÎÁÆ×éÏà±È£¬VizimproÖÎÁÆ×éPFSʵÏÖÁËͳ¼ÆѧÏÔÖøºÍÁÙ´²ÒâÒåµÄÑÓ³¤(ÖÐλPFS£º14.7¸öÔ vs 9.2¸öÔÂ)¡¢ËÀÍö»ò¼²²¡½øÕ¹·çÏÕÏÔÖø½µµÍÁË41%(HR=0.59[95%CI=0.47-0.74]£¬p<0.0001)£¬´ïµ½ÁËÑо¿µÄÖ÷ÒªÖյ㡣½ñÄê6ÔÂÔÚÃÀ¹úÁÙ´²Ö×Áöѧ»áÄê¶È»áÒé(ASCO2018)ÉϹ«²¼µÄOSÊý¾ÝÏÔʾ£¬VizimproÖÎÁÆ×éÖÐλOSΪ34.1¸öÔÂ(95%CI:29.5-37.7)£¬±ÈIressaÖÎÁÆ×é(ÖÐλOS£º26.8¸öÔÂ[95%CI:23.7-32.1])ÑÓ³¤ÁË7¸öÔ¡£ÖÎÁƵÚ30¸öÔÂʱ£¬VizimproÖÎÁÆ×éÉú´æÂÊΪ56.2%£¬IressaÖÎÁÆ×éΪ46.3%¡£ºá¿ç´ó¶àÊý»ùÏßÌØÕ÷µÄÑÇ×é·ÖÎöÓëÖ÷ÒªOS·ÖÎö½á¹ûÒ»Ö£¬°üÀ¨´æÔÚ³£¼ûµÄµÚ19ºÅºÍ20ºÅÍâÏÔ×ÓÑÇÍ»±äµÄ»¼Õß¡£

    °²È«ÐÔ·½Ã棬VizimproÖÎÁÆ×é×î³£¼ûµÄ(≥20%)²»Á¼·´Ó¦°üÀ¨£º¸¹Ðº(87%)¡¢Æ¤Õî(69%)¡¢¼×¹µÑ×(64%)¡¢¿ÚÇ»Ñ×(45%)¡¢Ê³Óû¼õÍË(31%)¡¢Æ¤·ô¸ÉÔï(30%)¡¢ÌåÖؼõÇá(26%)¡¢ÍÑ·¢(23%)¡¢¿ÈËÔ(21%)¡¢ðþÑ÷(21%)¡£VizimproÖÎÁÆ×éÓÐ27%µÄ»¼Õß·¢ÉúÑÏÖز»Á¼·´Ó¦£¬×î³£¼ûµÄ(≥1%)ÑÏÖز»Á¼·´Ó¦Îª¸¹Ðº(2.2%)ºÍ¼äÖÊÐԷμ²²¡(1.3%)¡£

    VizimproÊÇÒ»ÖÖ¿Ú·þ¡¢Ã¿ÈÕÒ»´Î¡¢²»¿ÉÄæ¡¢·º-ÈËÀà±íƤÉú³¤Òò×ÓÊÜÌå(pan-EGFR)ÀÒ°±ËἤøÒÖÖƼÁ(TKI)¡£½ñÄê4Ô£¬ÃÀ¹úFDAÒÑÊÚÓèVizimproÒ»ÏßÖÎÁÆЯ´øEGFR¼¤»îÍ»±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔNSCLCµÄÓÅÏÈÉó²é×ʸñ¡£Ä¿Ç°£¬VizimproÒ²ÔÚ½ÓÊÜÅ·ÖÞÒ©Æ·¹ÜÀí¾Ö(EMA)µÄ¼à¹ÜÉó²é¡£

    ARCHER 1050Ñо¿µÄÊ×ϯÑо¿Ô±¡¢Ïã¸Û´óѧÁÙ´²Ö×ÁöѧϵÖ÷ÈÎTony Mok½ÌÊÚ±íʾ£¬EGFRÍ»±äÍíÆÚNSCLCÊÇÒ»ÖÖ³£¼ûµÄ¼²²¡£¬ÌرðÊÇÔÚÑÇÖÞÈËȺÖУ¬ÐµÄÖÎÁÆ·½°¸½«×îÖÕʹ»¼ÕßÊÜÒæ¡£À´×ÔARCHER 1050Ñо¿µÄÊý¾ÝÏÔʾ£¬Vizimpro½«Îª´æÔÚ19ºÅÍâÏÔ×Óȱʧ»ò21ºÅÍâÏÔ×ÓL858RÖû»Í»±äµÄEGFRÍ»±äÐÍNSCLC»¼ÕßÌṩһÖÖеÄÒ»ÏßÖÎÁÆÑ¡Ôñ¡£

    ½üÄêÀ´£¬¾¡¹ÜЯ´øEGFR¼¤»îÍ»±äµÄNSCLC»¼ÕßÁÙ´²ÖÎÁÆÉÏÒÑÈ¡µÃÖØ´ó½øÕ¹£¬µ«¸Ã²¡ÈÔÈ»ÊÇÒ»ÖÖ¼«¾ßÌôÕ½ÐԵļ²²¡£¬¶ÔеÄÖÎÁÆ·½°¸´æÔÚ×ÅÆÈÇеÄÐèÇó¡£À´×ԹؼüÐÔÍ·¶ÔÍ·IIIÆÚÑо¿µÄOSÊý¾Ý·Ç³£ÁîÈ˹ÄÎ裬½ÓÊÜVizimproÖÎÁƵÄEGFR¼¤»îÍ»±äÐÍNSCLC»¼ÕßµÄÖÐλOS½Ó½ü3Ä꣬ÓëÄ¿Ç°ÁÙ´²Ò»ÏßÖÎÁÆÒ©ÎïIressaÏà±È¾ßÓÐÏÔÖøµÄ¸ÄÉÆ¡£

    »ÔÈðÈ«Çò²úÆ·¿ª·¢Ö×ÁöѧÊ×ϯ¿ª·¢¹ÙMace Rothenberg±íʾ£¬VizimproµÄ»ñÅú±êÖ¾×ÅÎÒÃÇÖÂÁ¦ÓÚÍƶ¯¾«×¼Ò½Ò©¿ª·¢ºÍ¸ÄÉÆÍ»±äÇý¶¯·Î°©»¼ÕßÔ¤ºó·½ÃæËù¸ºÔðŬÁ¦È¡µÃµÄ×îгɹû¡£Ä¿Ç°£¬»ÔÈðÒÑÑÐÖƳö2ÖÖ°ÐÏòÒ©Îï¿ÉÓÃÓÚÖÎÁÆ3ÖÖ²»Í¬ÀàÐÍÍ»±äÇý¶¯µÄ·Î°©£ºXalkori(crizotinib£¬¿ËßòÌæÄá)ÓÃÓÚÖÎÁÆALKÑôÐÔ»òROS1ÑôÐÔNSCLC£¬VizimproÓÃÓÚÖÎÁÆEGFRÍ»±äÐÍNSCLC¡£(ÉúÎï¹ÈBioon.com)

    Ô­Îijö´¦£ºU.S. FDA APPROVES VIZIMPRO® (DACOMITINIB) FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH EGFR-MUTATED METASTATIC NON-ALL CELL LUNG CANCER
·ÖÏí:

ÓÞÓÞѧ԰ÊôÓÚ´¿Ñ§Êõ¡¢·Ç¾­ÓªÐÔרҵÍøÕ¾£¬ÎÞÈκÎÉÌÒµÐÔÖÊ£¬´ó¼Ò³öÓÚѧϰºÍ¿ÆÑÐÄ¿µÄ½øÐн»Á÷ÌÖÂÛ¡£

ÈçÓÐÉæÇÖ·¸Öø×÷ȨÈ˵İæȨµÈÐÅÏ¢£¬Ç뼰ʱÀ´ÐŸæÖª£¬ÎÒÃǽ«Á¢¿Ì´ÓÍøÕ¾ÉÏɾ³ý£¬²¢ÏòËùÓгְæȨÕßÖÂ×îÉîǸÒ⣬лл¡£